Moderna Reveals How Effective Its Booster Dose Is Against The COVID-19 Omicron Variant
The company is also working on an Omicron-specific vaccine.
The new COVID-19 variant Omicron has put a damper on many holiday season plans, but Moderna has confirmed that its booster shot does show promise in amping up protection.
In a news release published on December 20, Moderna stated that the authorized booster shot increased antibody levels against the Omicron variant compared to the first and second doses.
"These data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring," said CEO Stéphane Bancel.
He added, "To respond to this highly transmissible variant, Moderna will continue to rapidly advance an Omicron-specific booster candidate into clinical testing in case it becomes necessary in the future."
The authorized 50 \u00b5g booster of mRNA-1273 increased neutralizing antibody levels against Omicron ~37-fold compared to pre-boost levels & a 100 \u00b5g dose of mRNA-1273 increased neutralizing antibody levels ~83-fold compared to pre-boost levels. Read more: https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Preliminary-Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant/default.aspx\u00a0\u2026pic.twitter.com/5big1gH6cN— Moderna (@Moderna) 1639994513
Moderna is also working on improving the booster shot to strengthen its protection against variants of concern. This includes testing the booster shot at the authorized 50 micrograms and doubling the dose to 100 micrograms.
So far, the company has found that although the approved 50-microgram booster appears to increase levels of Omicron-neutralizing antibodies 37-fold, a 100-microgram dose of the booster increased antibody levels 83-fold in comparison to pre-booster levels.
The booster candidates are currently in phase 2/3 of evaluation, with each study comprising 300-600 participants.
The reports also addressed the safety of the 100-microgram booster shot as studied in phase 2/3. The study showed that the 100-microgram booster was "generally safe and well tolerated."
However, the findings showed that the 100-microgram booster resulted in slightly more frequent adverse reactions than the 50-microgram booster.
In the news release, the company also promised to continue developing an Omicron-specific variant vaccine, which they hope to take to clinical trials by early 2022.
Health Canada has a robust website with all the latest information on COVID-19 vaccines and can answer any questions you may have.
This article's cover image was used for illustrative purposes only.
- Third Doses Of A COVID-19 Vaccine Will Be Available To Even ... ›
- Ontarians Should 'Reconsider' Holiday Plans Due To Growing ... ›
- Even More Ontarians Will Be Eligible To Book Their COVID-19 ... ›
- Justin Trudeau Says Enough Booster Doses Have Been Secured 'For Adults Across Canada' ›
- Ontario Will Reportedly Give Fourth Doses Of A COVID-19 Vaccine To Nursing Home Residents - Narcity ›
- A Woman Got COVID Twice In 20 Days & Scientists Say That's A New Record - Narcity ›